- Home
- AKAN vs SLRX Comparison
AKAN vs SLRX Comparison
Compare AKAN & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKAN
- SLRX
- Stock Information
- Founded
- AKAN 2021
- SLRX N/A
- Country
- AKAN Canada
- SLRX United States
- Employees
- AKAN N/A
- SLRX N/A
- Industry
- AKAN Medicinal Chemicals and Botanical Products
- SLRX Biotechnology: Pharmaceutical Preparations
- Sector
- AKAN Health Care
- SLRX Health Care
- Exchange
- AKAN Nasdaq
- SLRX Nasdaq
- Market Cap
- AKAN 2.9M
- SLRX 2.9M
- IPO Year
- AKAN 2022
- SLRX N/A
- Fundamental
- Price
- AKAN $3.29
- SLRX $4.64
- Analyst Decision
- AKAN
- SLRX
- Analyst Count
- AKAN 0
- SLRX 0
- Target Price
- AKAN N/A
- SLRX N/A
- AVG Volume (30 Days)
- AKAN 160.1K
- SLRX 120.9K
- Earning Date
- AKAN 10-29-2025
- SLRX 08-12-2025
- Dividend Yield
- AKAN N/A
- SLRX N/A
- EPS Growth
- AKAN N/A
- SLRX N/A
- EPS
- AKAN N/A
- SLRX N/A
- Revenue
- AKAN $836,664.00
- SLRX N/A
- Revenue This Year
- AKAN N/A
- SLRX N/A
- Revenue Next Year
- AKAN N/A
- SLRX N/A
- P/E Ratio
- AKAN N/A
- SLRX N/A
- Revenue Growth
- AKAN 97.47
- SLRX N/A
- 52 Week Low
- AKAN $2.91
- SLRX $4.57
- 52 Week High
- AKAN $8.75
- SLRX $108.00
- Technical
- Relative Strength Index (RSI)
- AKAN 38.53
- SLRX 31.34
- Support Level
- AKAN $3.35
- SLRX $4.61
- Resistance Level
- AKAN $3.86
- SLRX $6.28
- Average True Range (ATR)
- AKAN 0.39
- SLRX 0.46
- MACD
- AKAN -0.08
- SLRX 0.06
- Stochastic Oscillator
- AKAN 11.29
- SLRX 4.09
About AKAN Akanda Corp.
Akanda Corp is a cannabis cultivation, manufacturing, and distribution company. The company has three reportable segments: Cultivation, Distribution, and Corporate. A majority of its revenue is generated from the Distribution segment, which relates to the distribution of medical cannabis products, including cannabis oil and cannabis flower for medical use in the United Kingdom.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.